Societal CDMO Reports Inducement Grants for New Staff
06 avr. 2022 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation
21 mars 2022 07h00 HE
|
Recro Pharma, Inc.
With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers’ Goal of Delivering Impactful Medicines to SocietyNew...
Recro Reports Fourth Quarter and Year End 2021 Financial Results
01 mars 2022 16h05 HE
|
Recro Pharma, Inc.
Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele Grew Organic New Business by 63% in 2021; Grew...
Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility
23 févr. 2022 07h00 HE
|
Recro Pharma, Inc.
SAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to...
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
22 févr. 2022 16h05 HE
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...
Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention
26 janv. 2022 07h00 HE
|
Recro Pharma, Inc.
SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
Recro Reports Inducement Grants For New Staff
06 janv. 2022 16h05 HE
|
Recro Pharma, Inc.
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
03 janv. 2022 07h00 HE
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
Recro to Present at Stephens Annual Investment Conference
02 déc. 2021 07h00 HE
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...
Recro Reports Third Quarter 2021 Financial Results
09 nov. 2021 16h05 HE
|
Recro Pharma, Inc.
Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of...